2. Academic Validation
  3. 1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction

  • J Med Chem. 2017 Jul 13;60(13):5663-5672. doi: 10.1021/acs.jmedchem.7b00352.
Saleh Ahmed,  Andrew Ayscough,  Greg R Barker,  Hannah E Canning,  Richard Davenport,  Robert Downham,  David Harrison,  Kerry Jenkins,  Natasha Kinsella,  David G Livermore,  Susanne Wright,  Anthony D Ivetac 1,  Robert Skene 1,  Steven J Wilkens 1,  Natalie A Webster,  Alan G Hendrick
Affiliations

Affiliation

  • 1 Department of Computational Sciences and Crystallography, Takeda California Inc. , 10410 Science Center Dr., San Diego, California 92121, United States.
PMID: 28594552 DOI: 10.1021/acs.jmedchem.7b00352
Abstract

Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) Enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.

Figures
Products